Literature DB >> 29654394

Investigating clinical failure of core decompression with autologous bone marrow mononuclear cells grafting for the treatment of non-traumatic osteonecrosis of the femoral head.

Lihua Liu1, Fuqiang Gao2, Wei Sun3, Yunting Wang4, Qingyu Zhang1, Bailiang Wang2, Liming Cheng2, Zi-Rong Li2.   

Abstract

OBJECTIVE: This study aimed to analyze the clinical factors related to the failure of autologous bone marrow mononuclear cells grafting (BMMCG) following core decompression (CD) in early stage osteonecrosis of the femoral head (ONFH).
METHODS: In total, 148 patients (192 hips) underwent CD with autologous BMMCG for treatment of non-traumatic ONFH. The patients were classified by their ARCO staging and China-Japan Friendship Hospital (CJFH) typing system. All patients were clinically and radiographically followed up every three months during the first year and every six months in the following years. The clinical evaluation was conducted by pre- and post-operative Harris hip scores (HHS), while serial anteroposterior (AP) and frog lateral radiographs were used for post-operative radiographic evaluation.
RESULTS: There were 56 hips as clinical failure cases, and 50 hips (89.29%) of failure cases developed between three and ten months after operation. Based on CJFH classification system, type L2 showed more failure rate with 60.0% (9 of15). The Cox risk model showed that disease type was an independent risk factor for post-operative clinical failure (P = 0.042). Multivariate analysis of the Cox proportional-hazards model showed that type L1 had a hazard ratio (HR) of 0.286 (95% CI 0.100-0.816), type L3 with HR of 0.245 (95% CI 0.079-0.759), respectively.
CONCLUSION: Disease type is an important risk factor for autologous BMMCG combined with CD, and the degree of lateral pillar necrosis is a significant reference index for prognosis evaluation in early stage of ONFH.

Entities:  

Keywords:  Bone marrow; Osteonecrosis of the femoral head; Prognosis; Risk factor; Treatment

Mesh:

Year:  2018        PMID: 29654394     DOI: 10.1007/s00264-018-3918-7

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  20 in total

1.  Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis.

Authors:  P Hernigou; F Beaujean; J C Lambotte
Journal:  J Bone Joint Surg Br       Date:  1999-03

2.  Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study.

Authors:  Valérie Gangji; Viviane De Maertelaer; Jean-Philippe Hauzeur
Journal:  Bone       Date:  2011-07-29       Impact factor: 4.398

Review 3.  Which factors influence preservation of the osteonecrotic femoral head?

Authors:  Jay R Lieberman; Stephen M Engstrom; R Michael Meneghini; Nelson Fong SooHoo
Journal:  Clin Orthop Relat Res       Date:  2012-02       Impact factor: 4.176

Review 4.  Analysis of Cell Therapies Used in Clinical Trials for the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review of the Literature.

Authors:  Nicolas S Piuzzi; Jorge Chahla; Hao Jiandong; Morad Chughtai; Robert F LaPrade; Michael A Mont; George F Muschler; Cecilia Pascual-Garrido
Journal:  J Arthroplasty       Date:  2017-03-15       Impact factor: 4.757

5.  Multiple drilling compared with standard core decompression for avascular necrosis of the femoral head in sickle cell disease patients.

Authors:  Abdullah Al Omran
Journal:  Arch Orthop Trauma Surg       Date:  2013-03-15       Impact factor: 3.067

6.  Treatment of nontraumatic osteonecrosis of the femoral head with the implantation of core decompression and concentrated autologous bone marrow containing mononuclear cells.

Authors:  Bai-Liang Wang; Wei Sun; Zhen-Cai Shi; Nian-Fei Zhang; De-Bo Yue; Wan-Shou Guo; Shu-Qing Xu; Jin-Ning Lou; Zi-Rong Li
Journal:  Arch Orthop Trauma Surg       Date:  2009-07-21       Impact factor: 3.067

Review 7.  Osteonecrosis repair with bone marrow cell therapies: state of the clinical art.

Authors:  Philippe Hernigou; Charles-Henri Flouzat-Lachaniette; Jerome Delambre; Alexandre Poignard; Jerome Allain; Nathalie Chevallier; Helene Rouard
Journal:  Bone       Date:  2014-07-10       Impact factor: 4.398

8.  [S3 Guideline. Part 3: Non-Traumatic Avascular Necrosis in Adults - Surgical Treatment of Atraumatic Avascular Femoral Head Necrosis in Adults].

Authors:  U Maus; A Roth; M Tingart; C Rader; M Jäger; U Nöth; S Reppenhagen; C Heiss; J Beckmann
Journal:  Z Orthop Unfall       Date:  2015-08-05       Impact factor: 0.923

Review 9.  Stem Cell Therapy for the Treatment of Hip Osteonecrosis: A 30-Year Review of Progress.

Authors:  Philippe Hernigou; Matthieu Trousselier; François Roubineau; Charlie Bouthors; Nathalie Chevallier; Helene Rouard; Charles-Henri Flouzat-Lachaniette
Journal:  Clin Orthop Surg       Date:  2016-02-13

10.  Cell therapy of hip osteonecrosis with autologous bone marrow grafting.

Authors:  Philippe Hernigou; Alexandre Poignard; Sebastien Zilber; Hélène Rouard
Journal:  Indian J Orthop       Date:  2009-01       Impact factor: 1.251

View more
  4 in total

1.  Hip osteonecrosis: stem cells for life or behead and arthroplasty?

Authors:  Philippe Hernigou; Gildasio Daltro; Jacques Hernigou
Journal:  Int Orthop       Date:  2018-06-08       Impact factor: 3.075

2.  Comparison of the outcome of different bone grafts combined with modified core decompression for the treatment of ARCO II stage femoral head necrosis.

Authors:  Junming Wan; Yanqing Hu; Jiachun Li; Yuqing Zeng; Haiyong Ren
Journal:  Int Orthop       Date:  2022-05-10       Impact factor: 3.479

3.  The effect of the necrotic area on the biomechanics of the femoral head - a finite element study.

Authors:  Pengfei Wen; Yumin Zhang; Linjie Hao; Ju'an Yue; Jun Wang; Tao Wang; Wei Song; Wanshou Guo; Tao Ma
Journal:  BMC Musculoskelet Disord       Date:  2020-04-06       Impact factor: 2.362

4.  Knowledge structure and emerging trends on osteonecrosis of the femoral head: a bibliometric and visualized study.

Authors:  Haiyang Wu; Kunming Cheng; Linjian Tong; Yulin Wang; Weiguang Yang; Zhiming Sun
Journal:  J Orthop Surg Res       Date:  2022-03-28       Impact factor: 2.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.